Subtype
Tenosynovial Giant Cell Tumor, Diffuse Type
CI-CAN-00004065Explore in graph →
Non-malignant4 active trials
Loading cancer entity…
Subtype
CI-CAN-00004065Explore in graph →
Clinical trials
15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07707882 | Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor(NEXPERT) | not yet recruiting | Phase 2 | 84 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT05804045 | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) | active not recruiting | Phase 3 | 94 | Abbisko Therapeutics Co, LtdINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2026source: clinicaltrials
| NCT05059262 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor(MOTION) |
| active not recruiting |
| Phase 3 |
| 123 |
| Deciphera Pharmaceuticals, LLCINDUSTRY |
| 13 |
| Mar 20, 2026 |
| clinicaltrials |